Indeed, studies have shown that PI3K inactivation results in HER2 overexpression, or vice versa, and dual inhibition of HER2 and PI3K yields more optimal anticancer activity in breast cancer cell lines [38–40]. Here, ERBB2 is linked to breast carcinoma.